The current role of systemic chemotherapy in the primary treatment of head and neck cancer

Cancer Treatment Reviews

Volumn 41, Issue 3, 2015, Pages 217-221

  Busch, C J ^a   Tribius, S ^a   Schafhausen, P ^a   Knecht, R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Concurrent radiochemotherapy; Head and neck cancer; Induction chemotherapy; Organ preservation

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISTANT METASTASIS; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS;

CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84923148350     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.02.002     Document Type: Review

References (29)

1. Ferlay J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
2. Forastiere A.A., Trotti A. Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 1999, 91(24):2065-2066.
3. Pignon J.P., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92(1):4-14.
4. Posner M.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357(17):1705-1715.
5. Vermorken J.B., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357(17):1695-1704.
6. Ma J., et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol 2012, 48(11):1076-1084.
7. Wolf G.T., Gross Fisher S. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer (The Department of Veterans Affairs [VA] Laryngeal Cancer Study Group). N Engl J Med 1991, 324:1685-1690.
8. Pointreau Y., et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009, 101(7):498-506.
9. Lorch J.H., et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011, 12(2):153-159.
10. Posner M.R., et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 2009, 20(5):921-927.
11. Blanchard P., et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013, 31(23):2854-2860.
12. Hitt R., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005, 23(34):8636-8645.
13. Hitt R., J.J.G., A. Lopez-Pousa, A. Berrocal, C. Garcia Giron, A. Irigoyen, J. Sastre, J. Martinez, H. Cortes-Funes, J. Cruz-Hernandez, Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol, 2009. 27(15s).
14. Hitt R., et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014, 25(1):216-225.
15. Haddad R., et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013, 14(3):257-264.
16. Cohen E.E., et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014.
17. O'Sullivan B., et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013, 31(5):543-550.
18. Budach, W., et al., Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy as treatment of unresected locally advanced head and neck cancer squamous cell cancer (HNSCC): A meta-analysis of randomized trials. ASCO Meeting Abstracts, 2014. 32(15_suppl): p. 6012.
19. Paccagnella A., et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010, 21(7):1515-1522.
20. Ghi, M.G., et al., Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826). ASCO Meeting Abstracts, 2014. 32(15_suppl): p. 6004.
21. Dietz, A., et al., Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): First results of the phase II randomized DeLOS-II study. ASCO Meeting Abstracts, 2014. 32(15_suppl): p. 6016.
22. Forastiere A.A., et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013, 31(7):845-852.
23. Lefebvre J.L., et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013, 31(7):853-859.
24. Ang K.K., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363(1):24-35.
25. Lassen P., et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27(12):1992-1998.
26. Huang S.H., et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 2013, 49(1):79-85.
27. Forastiere, A.A., et al., Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. ASCO Meeting Abstracts, 2006. 24(18_suppl): p. 5517-.
28. Lefebvre J.L., et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012, 23(10):2708-2714.
29. Brockstein B., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004, 15(8):1179-1186.